Back to news

Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness

PR Newswire•20/11/2026•08:00 ET
0

Key Highlights

  • ➤TREMFYA Q4W and Q8W significantly improved BASDAI versus placebo at Week 24
  • ➤TREMFYA reduced MRI-assessed sacroiliac inflammation over two times more than placebo
  • ➤STAR enrolled 411 biologic-naïve adults with MRI-confirmed axial PsA
  • ➤No new safety signals emerged; overall safety matched TREMFYA’s established profile

Expert Statements

Mikkel Ostergaard, Clinical Professor of Rheumatology, University of Copenhagen; Consultant in Rheumatology and Chairperson of COPECARE

“Axial involvement in psoriatic arthritis can be difficult to identify and evaluate, leaving clinicians with limited evidence to guide patient selection for clinical trials and possibly treatment decisions”

Mikkel Ostergaard, Clinical Professor of Rheumatology, University of Copenhagen; Consultant in Rheumatology and Chairperson of COPECARE

“In the STAR study, TREMFYA showed significant improvements in patient-reported symptoms and MRI-assessed axial inflammation in the sacroiliac joints, backed by a well-characterized safety profile. Together, these findings provide important evidence to help inform treatment decisions for this debilitating and understudied manifestation of psoriatic arthritis.”

David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson

“Psoriatic arthritis is a complex disease that can affect patients in many ways, from skin and peripheral joint symptoms to irreversible joint damage to axial involvement”

David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson

“The STAR study brings new insight to axial PsA research showing that TREMFYA can improve axial symptoms and MRI-detected inflammation, while uniquely establishing evidence for an IL-23 inhibitor. Johnson & Johnson continues to pioneer new studies to challenge norms for patients, and these results further reinforce the role of TREMFYA in addressing the diverse manifestations of psoriatic arthritis.”

Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness PR Newswire

* TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study * TREMFYA demonstrated more than 2 times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in the sacroiliac joints, which connect the lower spine to the pelvis and are responsible for pain and stiffness * TREMFYA was evaluated in first-ever PsA study using objective MRI assessments to confirm and measure axial inflammation alongside patient-reported symptoms NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). TREMFYA met primary and major secondary endpoints that demonstrated significant improvement in axial symptoms compared to placebo and significant reduction of MRI-assessed inflammation in the sacroiliac joints.(1)(,a) The Phase 4 STAR study is the first and only dedicated randomized, double-blind, placebo-controlled study designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement in PsA confirmed by magnetic resonance imaging (MRI). The late-breaking results are being presented at the Emirates Society for Rheumatology (ESR) Annual Meeting.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in